|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:activeIngredient
|
gptkb:nefazodone
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:ATCCode
|
N06AX06
|
|
gptkbp:blackBoxWarning
|
liver failure
|
|
gptkbp:brand
|
gptkb:Dutonin
gptkb:Serzone
Nefadar
|
|
gptkbp:CASNumber
|
16673-34-0
|
|
gptkbp:chemicalFormula
|
C25H32ClN5O2
|
|
gptkbp:contraindication
|
gptkb:liver_disease
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugClass
|
phenylpiperazine
|
|
gptkbp:eliminationHalfLife
|
2-4 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nefazodone hydrochloride
|
|
gptkbp:interactsWith
|
gptkb:sirolimus
gptkb:cyclosporine
gptkb:phenytoin
gptkb:rifampin
gptkb:pimozide
gptkb:carbamazepine
gptkb:tacrolimus
gptkb:midazolam
gptkb:cisapride
gptkb:triazolam
gptkb:St._John's_Wort
gptkb:digoxin
statins
CYP3A4 inhibitors
alprazolam
terfenadine
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:marketedIn
|
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
serotonin antagonist and reuptake inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
drowsiness
liver toxicity
dry mouth
|
|
gptkbp:soldIn
|
gptkb:United_Kingdom
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
|
|
gptkbp:withdrawn
|
gptkb:Canada
gptkb:European_Union
|
|
gptkbp:withdrawnReason
|
risk of severe liver injury
|
|
gptkbp:bfsParent
|
gptkb:Nefazodone
|
|
gptkbp:bfsLayer
|
7
|